** Drug developer Eton Pharmaceuticals' ETON.O shares fall 2.2% to $13.39
** Company posts fourth-quarter net loss of 2 cents per share vs analysts' estimate of break even per share, according to data compiled by LSEG
** Company reports product revenue of $11.65 million vs est $10.53 million
** As of last close, Eton Pharma's shares have more than tripled in the past 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。